Arrowhead Pharma (NASDAQ:ARWR) shares traded during most recent session to reach at the closing price of $13.76. The stock exchanged hands on average of 2.47 Million shares, yielding a market cap of $1.26 Billion. Wall Street analysts covering the stock are projecting that the stock will reach $23.3 within the next 52-weeks. The mean target projections are based on 5 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Arrowhead Pharma (NASDAQ:ARWR) high price target of $25 and with a conservative view have low price target of $19.

Chardan Capital “Maintained” Arrowhead Pharma (NASDAQ:ARWR) in a research note issued to investors on 9/06/18 to Buy with price target of $24.5.

Additionally on 9/06/18 B. Riley FBR “Upgrades” Arrowhead Pharma (NASDAQ:ARWR) to Buy setting price target at $0 and on 8/08/18 B. Riley FBR “Maintained” the stock to Neutral at $18. Furthermore on 5/09/18 Cantor Fitzgerald “Upgrades” the stock to Overweight at $.

On the other hand the company has Relative Strength Index (RSI 14) of 30.78 along with Average True Range (ATR 14) of 1.57, Consequently Arrowhead Pharma (NASDAQ:ARWR)’s weekly and monthly volatility is 17.15%, 7.84% respectively. The company’s beta value is at 1.72.

In terms of Buy, Sell or Hold recommendations, Arrowhead Pharma (NASDAQ:ARWR) has analysts’ mean recommendation of 1.7. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Arrowhead Pharma (NASDAQ:ARWR)’s minimum EPS for the current quarter is at $-0.22 and can go high up to $-0.07. The consensus mean EPS for the current quarter is at $-0.11 derived from a total of 5 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.15 earnings per share for the same quarter during last year.

Previously Arrowhead Pharma (NASDAQ:ARWR) reported $-0.18 earnings per share (EPS) for the quarter, meeting the consensus estimate of $-0.18 by $0. The company posted an earnings surprise of 0%.

Arrowhead Pharma (NASDAQ:ARWR)’s revenue estimates for the current quarter are $8 Million according to 4 number of analysts, for the current quarter the company has high revenue estimates of $10.7 Million in contradiction of low revenue estimates of $700 Million. For the current year the company’s revenue estimates are $13.52 Million compared to low analyst estimates of $5.6 Million and high estimates of $16 Million according to 5 number of analysts.

Currently Arrowhead Pharma (NASDAQ:ARWR)’s shares owned by insiders are 2.6%, whereas shares owned by institutional owners are 61.3%. However the six-month change in the insider ownership was recorded -10.15%, as well as three-month change in the institutional ownership was recorded 3.3%.

Arrowhead Pharma (NASDAQ:ARWR)’s trailing twelve month revenues are $13.6 Million, whereas its price to sales ratio for the same period is 92.63. Its book value per share for the most recent quarter is $1.17 while its price to book ratio for the same period is 11.76, as for as the company’s cash per share for the most recent quarter is $0.66, however its price to cash per share ratio for the same period is 20.82. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.